 The FDA has issued a complete response letter CRL to Akebia Therapeutics Incs NASDAQ: AKBA marketing application NDA for vadadustat for anemia due to chronic kidney disease CKD. Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase. 